Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 11/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | BCR | P11274 | 1/20 | 0.34 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10454998 | 0.85 | CA2 (0.40) | HSD17B10ABCB1RPS6KA3 | |
| SCHEMBL3031530 | 0.80 | LPL (0.46) | CYP2C19 | |
| SCHEMBL172128 | 0.78 | ACHE (0.56) | ESR1ESR2RPS6KA3 | |
| SCHEMBL2910682 | 0.78 | LPL (0.49) | — | |
| SCHEMBL21374025 | 0.77 | PTGS2 (0.40) | ESR1ESR2 | |
| SCHEMBL10091341 | 0.76 | ESR2 (0.42) | ESR1ESR2APPCYP3A4CYP2C9 | |
| SCHEMBL9562009 | 0.76 | LPL (0.35) | ENPP2 | |
| SCHEMBL1513625 | 0.75 | ESR1 (0.43) | ESR1ESR2APPCYP3A4CYP2C9 | |
| SCHEMBL8831992 | 0.75 | ESR1 (0.48) | ESR1ESR2HSD17B10ABL1ABCB1 | |
| SCHEMBL30694739 | 0.75 | ESR1 (0.48) | ESR1ESR2HSD17B10ABL1ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2483370-B1 | POLYMERIZABLE COMPOUNDS AND THEIR USE IN LIQUID-CRYSTAL DISPLAYS | MERCK PATENT GMBH (DE) | 2015-07-15 | — | — | EP | disclosed |
| EP-2483370-B1 | POLYMERIZABLE COMPOUNDS AND THEIR USE IN LIQUID-CRYSTAL DISPLAYS | MERCK PATENT GMBH (DE) | 2015-07-15 | — | — | EP | disclosed |
| US-8940184-B2 | Polymerizable compounds and their use in liquid-crystal displays | MERCK PATENT GMBH (DE) | 2015-01-27 | — | — | US | disclosed |
| US-8940184-B2 | Polymerizable compounds and their use in liquid-crystal displays | MERCK PATENT GMBH (DE) | 2015-01-27 | — | — | US | disclosed |
| US-8940184-B2 | Polymerizable compounds and their use in liquid-crystal displays | MERCK PATENT GMBH (DE) | 2015-01-27 | — | — | US | disclosed |
| EP-2483370-A1 | POLYMERIZABLE COMPOUNDS AND THEIR USE IN LIQUID-CRYSTAL DISPLAYS | Merck Patent GmbH (DE) | 2012-08-08 | — | — | EP | disclosed |
| US-20120182516-A1 | POLYMERIZABLE COMPOUNDS AND THEIR USE IN LIQUID-CRYSTAL DISPLAYS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-07-19 | — | — | US | disclosed |
| US-20120182516-A1 | POLYMERIZABLE COMPOUNDS AND THEIR USE IN LIQUID-CRYSTAL DISPLAYS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-07-19 | — | — | US | disclosed |
| US-20120182516-A1 | POLYMERIZABLE COMPOUNDS AND THEIR USE IN LIQUID-CRYSTAL DISPLAYS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-07-19 | — | — | US | disclosed |
| WO-2011035842-A1 | POLYMERIZABLE COMPOUNDS AND THEIR USE IN LIQUID-CRYSTAL DISPLAYS | MERCK PATENT GMBH (DE) | 2011-03-31 | — | — | WO | disclosed |
| WO-2011035842-A1 | POLYMERIZABLE COMPOUNDS AND THEIR USE IN LIQUID-CRYSTAL DISPLAYS | MERCK PATENT GMBH (DE) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120182516-A1 | POLYMERIZABLE COMPOUNDS AND THEIR USE IN LIQUID-CRYSTAL DISPLAYS | VCL, LPXN, ACP3 | ESR1 408/4885ESR2 1598/4885ENPP2 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.